SB's Engerix B For Portuguese Program

9 October 1994

SmithKline Beecham says it has won a tender to provide the Portuguese Ministry of Health with 400,000 doses of its Hepatitis B vaccine, Engerix B.

The MoH's decision "is also affirmation of SB's significant and developing partnership with the Ministry," according to Cristiono Steidler, general manager of SB Pharmaceuticals in Portugal, who noted that earlier this year the company won the tender to provide over 2 million doses of its polio vaccine. "SB now has clear leadership in the polio and hepatitis B markets in Portugal," he said, which "will continue to pave the way for the introduction of new vaccines into the country."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight